NovoCare vs LillyDirect: the direct-pay showdown
The two cheapest brand channels in the market are the manufacturers' own pharmacies — but they sell different molecules with different pricing philosophies, different traps, and very different fulfillment reputations. The honest comparison.
First, the thing that decides it for most people
These programs don't sell the same drug. NovoCare is semaglutide (Wegovy, pen and pill; Ozempic for diabetes). LillyDirect is tirzepatide (Zepbound) and now orforglipron (Foundayo). If you and your prescriber have already settled on a molecule, the "choice" is made — this comparison matters most if you're genuinely open to either, or choosing which pill to start with.
And both share the same structural catch: they fill prescriptions, they don't write them. You bring your own prescriber, or add a one-off telehealth visit — the play our insurance guide and Sesame dossier cover.
Pricing philosophy: flat vs ladder
| NovoCare (Wegovy) | LillyDirect (Zepbound) | |
|---|---|---|
| Injectable | $349/mo flat, all standard doses (7.2 mg high-dose: $399) | $299 (2.5 mg) → $399 (5 mg) → $449 (7.5–15 mg) |
| Pill | Wegovy pill: $149 / $199 / $299 by dose | Foundayo: $149 → $349 by dose (promo tiers through 2026) |
| Intro offer | $199/mo for the first two fills (starter pen doses, new patients, through 12/31/26) | $299 at the 2.5 mg entry dose |
| The catch | Consult not included — bring a prescription | Maintenance pricing requires refilling within 45 days; lapse and 10–15 mg pens revert toward $699. Max 11 fills/yr |
The philosophies differ genuinely: Novo priced the pen flat — your cost doesn't climb as you titrate up. Lilly priced a ladder — cheaper to start, more expensive to maintain at higher doses, with a punctuality requirement attached. Over a year at full maintenance dose, that's roughly $4,188 at NovoCare's flat pen versus $5,388 at LillyDirect's top tiers — if you never miss the 45-day window.
The fulfillment reputations are not symmetrical
Our trust file gives NovoCare no channel-level review base yet (it launched March 2025 and has no standalone Trustpilot profile). LillyDirect has one, and it's rough: 1.6/5 across 94 reviews, an unclaimed profile where 82% of reviews are one-star — overwhelmingly fulfillment and logistics complaints, not pricing ones. Small sample, worth exactly what a small sample is worth — but it's the reason our LillyDirect dossier carries a flag and says "budget patience."
The Medicare wrinkle
If you're on Part D, the $50/month Bridge copay covers Wegovy pens and pills, Foundayo, and the Zepbound KwikPen only — not the single-dose vials. Bridge-eligible patients shouldn't be paying either cash price at all.
The verdict, by situation
- Prioritizing lowest entry price on a pill: tie at $149 — Wegovy pill 1.5 mg vs Foundayo 0.8 mg (promo). Different molecules; your prescriber's call, not a pricing site's.
- Planning for high-dose maintenance on an injectable: NovoCare's flat $349 beats LillyDirect's $449-with-conditions.
- Starting low and unsure you'll continue: LillyDirect's $299 entry is the cheapest brand injectable first month ($199 NovoCare intro aside).
- Bad at calendar discipline: NovoCare — the 45-day trap is real money.
- On tirzepatide specifically: there's no contest to have; LillyDirect is the direct channel, and its dossier's advice stands: set the refill reminder the day the box arrives.
Prices as listed on the dates shown on our index; both programs' terms change — checkout is the final word. Which molecule fits you is a clinician conversation, not ours. Neither manufacturer pays us anything — disclosure.